Neuroscience Video Recap—December 10, 2025

This biweekly Neuroscience video recap highlights major regulatory wins, late-stage clinical progress, early pipeline advances, and industry partnerships shaping next-generation therapies.

🎯 Watch Our Video Summary Capturing Neuroscience News from the Last Two Weeks

Dive deeper

🗓️ Explore weekly details and sources

Week 26 November–2 December 2025
Week 3–9 December 2025

📚 View the full Neuroscience archive on our research hub page.

Transcript

Welcome to the latest edition of Neuroscience Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.

AbbVie’s Phase 3 ECLIPSE study shows that atogepant is significantly superior to placebo for achieving pain freedom in the acute treatment of migraine. The study demonstrated that atogepant provided 24.3% pain freedom at two hours, compared to just 13.1% for the placebo group. This promising result positions atogepant as a potential new option for acute migraine relief, with European Medicines Agency approval pending.

Lynk Pharmaceuticals has received FDA Investigational New Drug approval for its brain-penetrant TYK2 inhibitor, LNK01006. This allosteric inhibitor targets neuroinflammatory diseases such as multiple sclerosis, showing promising preclinical results. LNK01006’s potential to target inflammatory pathways relevant to these diseases makes it an exciting new prospect for human trials.

GEN Pharmaceuticals has reported positive Phase 1 data for its drug SUL-238, developed for Alzheimer’s and other neurodegenerative diseases. The Phase 1 trial confirmed SUL-238’s safety, tolerability, and its ability to penetrate cerebrospinal fluid, making it a strong candidate for further clinical trials. This mitochondria-directed drug could potentially provide a novel treatment approach for Alzheimer’s and Parkinson’s diseases.

Johnson & Johnson has received European Commission approval for IMAAVY® (nipocalimab) as a treatment for generalized myasthenia gravis. Nipocalimab offers up to 20 months of sustained disease control in patients, significantly reducing IgG levels in pivotal studies. This approval provides a new treatment option for patients with anti-AChR or anti-MuSK antibody-positive generalized myasthenia gravis.

Bristol Myers Squibb is continuing its ADEPT-2 Phase 3 study for psychosis associated with Alzheimer’s disease. After reviewing data from irregular sites and enrolling additional patients, the study will test Cobenfy as a potential treatment for this unmet need. The ongoing trial represents an important step forward in addressing Alzheimer’s psychosis, with additional results expected by 2026.

Eli Lilly has entered into a $40 million partnership with Indiana University to expand access to clinical trials and advance Alzheimer’s research in Indiana. This five-year collaboration aims to create an AI-enabled clinical trial system, focusing on neurological diseases and other therapeutic areas. This initiative positions Indiana as a leader in clinical research and will accelerate access to life-saving treatments.

Kallyope has announced positive Phase 2b results for its acute migraine treatment, Elismetrep. This drug works through a novel mechanism, targeting TRPM8 antagonism. The favorable clinical outcomes and good tolerability make Elismetrep a promising new treatment option for migraine patients, with additional studies planned for mid-2026.

Lundbeck presented long-term data at AES 2025 showing that Bexicaserin provides sustained seizure reduction in rare childhood-onset epilepsies, including Developmental and Epileptic Encephalopathies. The data showed a sustained reduction in seizure frequency over two years, along with favorable safety results, making Bexicaserin a potential first-in-class treatment for drug-resistant childhood-onset epilepsies.

Stay ahead in Neuroscience research! Like, share, and subscribe for our updates. Visit www.lqventures.com
or email us at info@lqventures.com
for expert healthcare consulting. See you next time!

Why It Matters

AbbVie’s Atogepant [1] could revolutionize acute migraine treatment, providing significant pain relief where current options are insufficient.
Lynk Pharmaceuticals [2] has developed a promising TYK2 inhibitor, which could treat neuroinflammatory diseases by crossing the blood-brain barrier.
GEN Pharmaceuticals [3] is advancing SUL-238, a novel drug with strong potential for treating Alzheimer’s and other neurodegenerative diseases.
Johnson & Johnson’s IMAAVY® [4] provides a much-needed treatment option for gMG patients, offering long-term relief and improved disease control.
Bristol Myers Squibb’s ADEPT-2 study [5] remains on track to deliver a new treatment option for Alzheimer’s-related psychosis.
Eli Lilly & Indiana University’s partnership [6] will enhance clinical trial access, providing patients with cutting-edge treatments and advancing Alzheimer’s research.
Kallyope’s Elismetrep [7] could significantly impact migraine care, offering new treatment options with its innovative mechanism of action.
Lundbeck’s Bexicaserin [8] offers hope for patients with rare childhood-onset epilepsies, providing long-term seizure control with minimal side effects.

🗓️ Explore weekly details and sources

Week 26 November–2 December 2025
Week 3–9 December 2025

📚 View the full Neuroscience archive on our research hub page.

FAQ

What are the results from AbbVie’s Phase 3 ECLIPSE study?

AbbVie’s Atogepant showed superior pain freedom in treating acute migraine, with pain relief at 2 hours significantly better than placebo, supporting its potential for broader use in Europe [1].

What makes LNK01006 unique in treating neuroinflammatory diseases?

LNK01006 is a brain-penetrant TYK2 inhibitor that selectively targets inflammatory pathways in the central nervous system, holding promise for conditions like multiple sclerosis [2].

What are the key findings from GEN’s Phase 1 trial of SUL-238?

SUL-238 demonstrated an excellent safety profile and high cerebrospinal fluid penetration, making it a promising candidate for treating Alzheimer’s and Parkinson’s [3].

How does nipocalimab help gMG patients?

Nipocalimab offers long-term disease control for generalized myasthenia gravis, with up to 20 months of sustained symptom relief, particularly for patients with anti-AChR or anti-MuSK antibodies [4].

Why is the ADEPT-2 study important for Alzheimer’s psychosis?

The ADEPT-2 study aims to evaluate Cobenfy as a treatment for psychosis associated with Alzheimer’s, an area with limited effective treatments [5].

How will the Lilly-IU partnership benefit patients?

The partnership aims to build an AI-enabled clinical trial ecosystem and enhance neurological health resources, improving Alzheimer’s care and expanding access to innovative treatments [6].

What results were seen with Elismetrep in treating migraines?

Elismetrep demonstrated a competitive efficacy profile in acute migraine treatment, with no safety concerns, positioning it for future registration studies [7].

What long-term effects did Lundbeck observe with Bexicaserin?

Lundbeck’s Bexicaserin showed sustained seizure reduction in patients with Developmental and Epileptic Encephalopathies, offering hope for those with few treatment options [8].

Entities / Keywords

Atogepant, AbbVie, migraine, ECLIPSE study
LNK01006, Lynk Pharmaceuticals, TYK2 inhibitor, neuroinflammatory diseases
SUL-238, GEN Pharmaceuticals, Alzheimer’s, Parkinson’s
IMAAVY®, nipocalimab, generalized myasthenia gravis, Johnson & Johnson
ADEPT-2, Cobenfy, Alzheimer’s psychosis, Bristol Myers Squibb
Eli Lilly, Indiana University, clinical trials, Alzheimer’s disease
Elismetrep, migraine, Kallyope
Bexicaserin, childhood-onset epilepsies, Lundbeck